For all the latest news about TriviumVet and our products see our News section below.

TV sign shot LGTB.jpeg

check out our Funding announcement below….

Funding announcement

Check out the Sunday Business Post for our exclusive funding announcement

Listen to Louise and Tom talk all things pets with Architects of Business podcast

Listen to our co-founders talk all things pets and pharmaceuticals on

news tavocept.png

Trivium Vet sign worldwide exclusivity license agreement with Bionumerik

Under the worldwide license agreement TriviumVet are granted exclusive rights to the Tavocept drug compound for all veterinary applications. Research is ongoing for multiple applications of the product in both the canine and feline species.

Louise Grubb co-authors paper on ground-breaking Tavocept veterinary application

Human oncology drug Tavocept has been clinically evaluated for use in veterinary incidences of TCC (Transitional Cell Carcinoma). The study found that Tavocept decreased diuresis time and volume in dogs with bladder cancer receiving Cisplatin.